http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110922450-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110922450-B |
| titleOfInvention | PSMA activated antitumor prodrug CPT-X and preparation method and application thereof |
| abstract | The invention provides a compound with a structural general formula 1, a preparation method thereof and application thereof in preparing antitumor drugs. The PSMA activated prodrug CPT-HT-J-ZLn shows strong cytotoxic selectivity to PSMA positively expressed and PSMA negatively expressed tumor cells, and the activity of the PSMA activated prodrug on LNCaP-FGC positively expressed tumor cells is stronger than that of PSMA negatively expressed tumor cells such as PC-3, DU145, HepG2, Hela and MCF-7. Wherein the compound CPT-HT-J-ZL 12 For LNCaP-FGC (IC) 50 ＝1.00±0.20μM)(PSMA + ) Respectively, HepG2 (IC) of cells negatively expressing PSMA 50 ＞40.00μM)，Hela(IC 50 ＞40.00μM)，MCF‑7(IC 50 ＝21.68±4.96μM)，DU145(IC 50 5.40 ± 1.22 μ M) and PC-3 (IC) 50 42.96 ± 3.69 μ M) of 40,40,21,5 and 40 times. |
| priorityDate | 2018-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 112.